Abstract

Methods The MRI images, genetic data, and clinical data of 152 patients with GBM were analyzed. 122 patients from the TCIA dataset (training set: n = 82; validation set: n = 40) and 30 patients from local hospitals were used as an independent test dataset. Radiomics features were extracted from multiple regions of multiparameter MRI. Kaplan-Meier survival analysis was used to verify the ability of the imaging signature to predict the response of GBM patients to radiotherapy before an operation. Multivariate Cox regression including radiomics signature and preoperative clinical risk factors was used to further improve the ability to predict the overall survival (OS) of individual GBM patients, which was presented in the form of a nomogram. Results The radiomics signature was built by eight selected features. The C-index of the radiomics signature in the TCIA and independent test cohorts was 0.703 (P < 0.001) and 0.757 (P = 0.001), respectively. Multivariate Cox regression analysis confirmed that the radiomics signature (HR: 0.290, P < 0.001), age (HR: 1.023, P = 0.01), and KPS (HR: 0.968, P < 0.001) were independent risk factors for OS in GBM patients before surgery. When the radiomics signature and preoperative clinical risk factors were combined, the radiomics nomogram further improved the performance of OS prediction in individual patients (C‐index = 0.764 and 0.758 in the TCIA and test cohorts, respectively). Conclusion This study developed a radiomics signature that can predict the response of individual GBM patients to radiotherapy and may be a new supplement for precise GBM radiotherapy.

Highlights

  • Glioblastoma is the most common malignant tumour of the central nervous system in adults

  • In order to test the accuracy of this distribution, Kaplan survival analysis was performed in 102 patients who received radiotherapy

  • 122 cases from the the cancer imaging database (TCIA) dataset were divided into the resistance group (RR) group (13 cases) and the radiotherapy effective group (RE) group (109 cases)

Read more

Summary

Introduction

Glioblastoma is the most common malignant tumour of the central nervous system in adults. The current radiotherapy plan still assumes that each patient benefits from the same dose plan [6], ignoring the heterogeneity of individual tumour patients It means that clinical practice needs a marker that can predict the response of radiotherapy to lead to more personalized clinical decision making or dose adjustments for patients. Radiotherapy has become one of the main treatment methods for cancer, there is no noninvasive method to predict the radiotherapeutic response of individual glioblastoma (GBM) patients before surgery. Multivariate Cox regression including radiomics signature and preoperative clinical risk factors was used to further improve the ability to predict the overall survival (OS) of individual GBM patients, which was presented in the form of a nomogram. When the radiomics signature and preoperative clinical risk factors were combined, the radiomics nomogram further improved the performance of OS prediction in individual patients (C‐index = 0:764 and 0.758 in the TCIA and test cohorts, respectively). This study developed a radiomics signature that can predict the response of individual GBM patients to radiotherapy and may be a new supplement for precise GBM radiotherapy

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call